The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues.
The expression of PKM1 and PKM2 in developing, benign, and cancerous prostatic tissues.
复制标题
PKM1 和 PKM2 在发育中、良性和癌性前列腺组织中的表达。
DOI：
10.1101/2023.09.27.559832
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Yu,Xiuping
中科院分区：
文献类型：
--
作者：
Li,Lin;Cheng,Siyuan;Yeh,Yunshin;Shi,Yingli;Henderson,Nikayla;Price,David;Gu,Xin;Yu,Xiuping
Neuroendocrine prostate cancer (NEPCa) is the most aggressive type of prostate cancer (PCa). However, energy metabolism, one of the hallmarks of cancer, in NEPCa has not been well studied. Pyruvate kinase M (PKM), which catalyzes the final step of glycolysis, has two main splicing isoforms, PKM1 and PKM2. In this study, using immunohistochemistry, immunofluorescence staining, and bioinformatic analysis, we examined the expression of PKM1 and PKM2 in mouse and human prostatic tissues, including developing, benign, and cancerous prostate. We found that PKM2 was the predominant isoform expressed throughout prostate development and PCa progression, with slightly reduced expression in murine NEPCa. PKM1 was mostly expressed in stromal cells but low-level PKM1 was also detected in prostate basal epithelial cells. Its expression was absent in the majority of prostate adenocarcinoma (AdPCa) specimens but present in a subset of NEPCa. Additionally, we evaluated the mRNA levels of ten PKM isoforms that express exon 9 (PKM1-like) or exon 10 (PKM2-like). Some of these isoforms showed notable expression levels in PCa cell lines and human PCa specimens. These findings lay the groundwork for understanding the metabolic changes in different PCa subtypes.
